

Use of Antifungals Other Than Amphotericin B for Invasive Fungal Infections in Neonates and Children

Jeeson C Unni

ABSTRACT

Antifungal therapy for neonates, children, and adolescents, especially in those with primary or secondary immunodeficiencies having invasive fungal infections, is possible today due to the advent of newer antifungals. Studies of antifungals in the pediatric age-group are limited to those for cutaneous fungal infections. Although there are a few studies on the pharmacokinetics and safety, these drugs are used off-label, and most dosage recommendations are extrapolated from the adult data. A review of the use of antifungals other than amphotericin B for treatment of invasive fungal infections in pediatrics is the focus of this article.

Keywords: Antifungal agents, Caspofungin, Children, Fluconazole, Itraconazole, Neonate.

Pediatric Infectious Disease (2021): 10.5005/jp-journals-10081-1256

INTRODUCTION

The need for newer antifungals and the issues regarding the pharmacologic characteristics of antifungals in neonates and children were discussed in the article on amphotericin B in the last issue.¹

Dosing Strategies

A number of dosing strategies have been tried of which probably the most accurate is that based on surface area of the child; assessment of surface area of newborn child is difficult and often not accurate. The various strategies used for the various antifungals discussed in this review are listed in Table 1.² Note that most dosages are calculated on a "mg kg⁻¹" basis, which carries a significant risk of underdosing in neonates and children if the reference dose is the adult dosage. In case of micafungin, the dose is bracketed for ranges of weights and/or ages that could result in erroneous dosing in the extremes of the given range.

Classification of Antifungals According to the Mechanism of Action

The antifungal drugs are classified into 3 groups: antifungal agents acting on plasmatic membranes (azoles, polyenes), drugs acting on synthesis of nucleic acids (5-fluorocytosine), or those acting on fungal cell walls (echinocandins).³

Antifungal Agents, Other Than Amphotericin B, Currently Available for Treating IFI in Neonates and Children

Antifungals for systemic use other than amphotericin B include fluconazole capsule, oral suspension and intravenous (IV), itraconazole as capsule and IV, oral cyclodextrin suspension and IV cyclodextrin (if these formulations are available), IV caspofungin, and IV micafungin. The specific indications for each of these antifungals are also detailed in Table 1.²

IAP Drug Formulary, Aster Medcity, Kochi, Kerala, India

Corresponding Author: Jeeson C Unni, IAP Drug Formulary, Aster Medcity, Kochi, Kerala, India, Phone: +91 9847245207, e-mail: jeeson1955@gmail.com

How to cite this article: Unni JC. Use of Antifungals Other Than Amphotericin B for Invasive Fungal Infections in Neonates and Children. *Pediatr Inf Dis* 2021;3(1):38–42.

Source of support: Nil

Conflict of interest: None

Drug Monographs of Antifungals Other Than the Polyenes (Amphotericin B) with Reference to Use in IFI in Neonates and Children

Flucytosine [5FC, 5-fluorocytosine]

Rapid development of resistance to flucytosine occurs when it is administered as a standalone drug in the treatment of ISI. Therefore, it is advisable that flucytosine be administered in combination with other antifungal agents. The main advantage of this drug is its property to achieve high levels in tissues (including CSF and urine) and thereby be useful adjuvants to first-line drugs in treating cryptococcal meningitis or candida infections in central nervous system and urinary tract,^{4–6} even in neonates⁷ although a study cast doubts on its effectiveness in treating HCME.⁸

The fact that flucytosine is poorly tolerated and causes severe gastrointestinal upset, in turn delaying early oral feeding in neonates, must be factored when deciding to use the drug in the newborn period. Concentration-dependent myelotoxicity—aplastic anemia, leukopenia, and thrombocytopenia—and hepatotoxicity are the most severe side effects of flucytosine, possibly avoidable with close monitoring to maintain 5-FC concentrations at <100 mg/L and reversible with drug discontinuation or reduction of dose in adults;⁹ no data on this is thus far available in children.

Table 1: Antifungal agents, other than amphotericin B, currently available for treating IFI in neonates and children²

Drug	Formulation	Adult regimen	Neonatal regimen	Pediatric regimen	Indications
Fluconazole	Capsule, oral suspension and IV injection	Prophylaxis: 200 mg daily Treatment: 400–800 mg daily	Newborn (0–14 days) maximum dose 12 mg kg ⁻¹ every 72 h Newborn (15–27 days) maximum dose 12 mg kg ⁻¹ every 48 h Consideration given to a loading dose 25 mg kg ⁻¹	Infants and children 6–12 mg kg ⁻¹ daily	<ul style="list-style-type: none"> Mucosal candidiasis (oropharyngeal, esophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of recurrence.
Itraconazole	Capsule, oral cyclodextrin suspension and IV cyclodextrin injection	200 mg twice daily	Very limited data with a single report describing the use of 5 mg kg ⁻¹ twice daily	2.5–5 mg kg ⁻¹ twice daily	<ul style="list-style-type: none"> Very limited data - preferable to use other antifungals whenever possible Oral and/or esophageal candidosis in HIV-positive or other immunocompromised patients. As prophylaxis of deep fungal infections (in cases where indicated) that are expected to be susceptible to itraconazole, when standard therapy is considered inappropriate (prophylaxis against aspergillosis - little evidence)
Voriconazole	Capsule, oral suspension and IV cyclodextrin injection	Oral dosing: 400 mg twice daily for two doses, then 200 mg twice daily i.v. dosing: 6 mg kg ⁻¹ twice daily for two doses, then 4 mg kg ⁻¹ twice daily	Very limited data with dosages ranging from 3.4–14.7 mg kg ⁻¹	Oral dosing: 9 mg kg ⁻¹ (maximum 350 mg in 12 hours) i.v. dosing: 9 mg kg ⁻¹ twice daily for two doses, then 8 mg kg ⁻¹ twice daily	<ul style="list-style-type: none"> Only licensed for children >2 years. Invasive aspergillosis. Candidaemia in non-neutropenic patients. Fluconazole-resistant serious invasive <i>Candida</i> infections (including <i>C. krusei</i>). Serious fungal infections caused by <i>Scedosporium</i> spp. and <i>Fusarium</i> spp.
Caspofungin	IV injection	70 mg loading dose, followed by 50 mg daily	Limited data for use of caspofungin in neonates and younger children with doses of 25 mg m ⁻² daily (<3 months) and 50 mg m ⁻² daily (3–11 months).	Children 12 months–17 years loading dose 70 mg m ⁻² followed by 50 mg m ⁻² daily (maximum dose 70 mg)*	<ul style="list-style-type: none"> Invasive candidiasis

Contd...

Contd...

Drug	Formulation	Adult regimen	Neonatal regimen	Pediatric regimen	Indications
				*Increased to 70 mg m ⁻² daily if clinical response inadequate.	<ul style="list-style-type: none"> Invasive aspergillosis refractory to or intolerant of amphotericin B and/or itraconazole. (refractory disease is defined as progression of infection or failure of clinical improvement after a minimum of 7 days of therapeutic doses of effective antifungal therapy). Empirical therapy for presumed fungal infections (<i>Candida</i> or <i>Aspergillus</i>) in febrile neutropenia.
Micafungin	IV injection	Treatment of invasive candidiasis: 100 mg daily, increased to 200 mg daily if clinical response inadequate Treatment of esophageal candidiasis: 150 mg daily Prophylaxis of <i>Candida</i> infection in patients undergoing allogeneic hematopoietic stem cell transplantation or patients who are expected to have neutropenia for 10 or more days.	4–10 mg kg ⁻¹ * *Higher dosages may be required for CNS infection	Body weight >40 kg: adult dosing Body weight <40 kg: Invasive candidiasis 2 mg kg ⁻¹ daily** Esophageal candidiasis 3 mg kg ⁻¹ daily Prophylaxis: 50 mg day ⁻¹ **Increased to 4 mg kg ⁻¹ daily if clinical response inadequate	<ul style="list-style-type: none"> Invasive candidiasis in children <16 years, including neonates. Prophylaxis of <i>Candida</i> infection in patients undergoing allogeneic hematopoietic stem cell transplantation or patients who are expected to have neutropenia for 10 or more days.
Flucytosine	IV or oral		50 mg/kg every 12 hours 50 mg/kg every 12 hours.	Child: Usual dose 50 mg/kg every 6 hours usually for not more than 7 days, alternatively 25–37.5 mg/kg every 6 hours usually for not more than 7 days, lower dose may be sufficient for sensitive organisms 25 mg/kg every 6 hours for 2 weeks	Systemic yeast and fungal infections Adjunct to amphotericin in severe systemic candidiasis and in other severe or long-standing infections Cryptococcal meningitis (adjunct to amphotericin)

*Note comment in indications column

**The studies on higher doses in children are lacking

Triazoles

This category of drugs enabled the treating pediatrician the much needed oral therapy in their armamentarium to manage

ISI; drugs of choice till then were the parenteral polyenes and echinocandins. Since *Candida albicans* is the predominant fungal pathogen encountered in the neonate, fluconazole, which affords

excellent candida cover, has become the triazole most extensively used in neonatology.¹⁰ The drug has been extensively studied and recommended for prophylaxis against invasive fungal infection in preterm infants in neonatal intensive care units (NICUs).¹¹ Fluconazole penetrates the central nervous system (including CSF) and the urine and may therefore be useful for treatment of infections at these sites.^{12–14}

Fluconazole is also used orally or IV for prevention of fungal infections in immunocompromised patients, including children with acute leukemia, myelodysplastic syndromes, and those undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT). Neonate up to 14 days and after 14 days up to 28 days may be given 3–12 mg/kg every 72 hours and 3–12 mg/kg every 48 hours, respectively, the dose being adjusted according to extent and duration of neutropenia. For children, commence the treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count is in desirable range at a dose of 3–12 mg/kg daily (max. per dose 400 mg), dose given according to extent and duration of neutropenia. But since high doses, resulting in adverse reactions, are required in these conditions, and since it does not cover some strains of *Candida* like *C. krusei* and *C. glabrata*, newer fluconazole drugs are being considered.¹⁵

Fluconazole is also used for the prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy at 6 mg/kg (max 600 mg) orally or IV.

Fluconazole has no inherent activity against *Aspergillus* spp (very occasional pathogen in newborn) and the extended spectrum triazoles with anti-*Aspergillus* activity—itraconazole, voriconazole, and posaconazole—are used in that setting.¹⁶ These extended spectrum triazoles are used extensively in children. While the overall rates of triazole resistance remain low, there are increasing reports of resistance to fluconazole in the neonates¹⁷ and concerns emerging regarding the possibility of *Aspergillus* spp. resistance to the extended spectrum triazoles.^{18,19}

Itraconazole is not generally used in the NICU. There are only limited pharmacokinetic data for itraconazole administered to children aged >6 months. Its use is mainly for superficial keratinizing fungal infection and not for ISI.

Itraconazole, voriconazole, and posaconazole showed comparable efficacy as antifungal prophylaxis in pediatric patients after allogeneic HSCT.²⁰

Voriconazole and posaconazole are effective in treating infections by fluconazole-resistant *Candida* spp. and molds, *Aspergillus* spp., and *Fusarium* spp.^{15,18,19,21} Unlike voriconazole, posaconazole has activity against the Mucorales order and is used for the treatment of mucormycosis and disseminated zygomycosis.^{22,23} Voriconazole is also approved for use as salvage therapy for *Scedosporium apiospermum* osteoarticular infections in children following injury.²⁴ Voriconazole and posaconazole therapeutic drug monitoring (TDM) can be utilized to improve patient outcomes and, in the case of voriconazole, to limit toxicity.

Voriconazole is a well-tolerated drug. The most frequently occurring adverse drug reactions (ADRs) are visual disturbances (23–35%) demonstrated as color vision change, blurred vision, scotoma, and photophobia. These reactions appear at the time of administration and return to normal after about 30 minutes. ADRs that occur more often during treatment with voriconazole than posaconazole are sinusitis, hypoglycemia, hypokalemia, depression, hallucinations, anxiety, headache and dizziness, peripheral

edema, thrombophlebitis, hypotension, acute respiratory distress syndrome, pulmonary edema, jaundice, backache, acute renal failure, and hematuria.²⁵ In general, posaconazole has a very good safety and tolerability profile.²⁶ In clinical trials, posaconazole was also particularly well tolerated. The main side effects experienced by the participants were gastrointestinal distress (nausea, vomiting, and diarrhea), neutropenia, and elevated liver enzymes.

Echinocandins

This group includes caspofungin, micafungin, and anidulafungin.

Candida albicans and *C. glabrata* are sensitive to echinocandins. Of late, resistance among the latter is being reported.²⁷ These strains of *C. glabrata* are frequently triazole resistant and are difficult to treat. Resistance to echinocandins is due to mutations resulting in substitutions of amino acids in the Fks1 subunit of 1,3-β-D-glucan synthase which render them inactive.²⁸ *Candida parapsilosis*, in which Fks1p harbors an intrinsic amino acid change at position 660 of the hot spot 1 region, is less sensitive to echinocandins.²⁹

The recommendation for use in neonates is not clear. They seem safe in the newborn, but more data on its pharmacokinetics and dosing are required before regularizing its use in this age-group. The echinocandin most studied in the neonate is micafungin for the treatment of invasive candidiasis;³⁰ a higher dose is recommended for HCME³¹ as shown in Table 1. However, the predominance of *C. parapsilosis* in the nursery³² needs to be factored when using echinocandins in neonatal fungal infections.

There being very little difference in-between these three echinocandins, they may be used interchangeably in older children. There is limited evidence for use of anidulafungin in neonates.³³

In children, some experts have started recommending this group of antifungals as firstline for ISI caused by *Candida* species and as salvage therapy for invasive aspergillosis.³⁴ But their use as a single agent in the treatment of invasive pulmonary aspergillosis in the immunocompromised is uncertain.³⁵

Caspofungin is approved for empiric therapy of febrile neutropenia, and micafungin is licensed for antifungal prophylaxis in stem cell transplantation.³⁶

SUMMARY

Invasive fungal infections are serious, difficult to diagnose, difficult to confirm bacteriologically, life-threatening conditions throughout childhood, especially in the neonate and the immunocompromised child. They present complex therapeutic dilemmas, which antifungal to choose in a given setting. If the diagnosis is missed, ISI could result in death. Death or severe long-term sequelae occurs even with the best of care and the selection of the most appropriate antifungal. Although some recommendations have been made regarding the spectrum, pharmacokinetics, and dosing of antifungals in neonates and children, many more well-designed studies are required to elucidate data on dosing strategies, drug resistance, mono- or combination antifungal therapy.

REFERENCES

1. Unni JC. Review of amphotericin B for invasive fungal infections in neonates and children. *Pediatr Infect Dis* 2020. DOI: 10.5005/jp-journals-10081-1240.
2. Lestner JM, Smith BP, Cohen-Wolkowicz M, et al. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. *Br J Clin Pharmacol* 2013;75(6):1381–1395. DOI: 10.1111/bcp.12025.

3. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clin Microbiol Rev* 1999;12(4):501–517. DOI: 10.1128/CMR.12.4.501.
4. Johnson KC, Barone JG. Management of obstructive fungal pyelonephritis in infants. *Urology* 2006;67(2):424.e7–424.e9. DOI: 10.1016/j.urology.2005.09.017.
5. Schwarz P, Janbon G, Dromer F, et al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of *Cryptococcus neoformans*. *Antimicrob Agents Chemother* 2007;51(1):383–385. DOI: 10.1128/AAC.00446-06.
6. Liu Y, Kang M, Ye H, et al. Analysis on clinical characteristics and drug resistance of *Candida parapsilosis* bloodstream infections in west china hospital, China, from 2012 to 2015. *Mycol Med* 2018;28(1):222–226. DOI: 10.1016/j.mycmed.2017.05.001.
7. Merry M, Boulware DR. Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a cost-effectiveness analysis. *Clin Infect Dis* 2016;62(12):1564–1568. DOI: 10.1093/cid/ciw151.
8. Benjamin DK, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18–22 months. *Pediatrics* 2006;117(1):84–92. DOI: 10.1542/peds.2004-2292.
9. Vermes A, Guchelaar H, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. *J Antimicrob Chemother* 2000;46(2):171–179. DOI: 10.1093/jac/46.2.171.
10. Luparia M, Landi F, Mesini A, et al. Fungal ecology in a tertiary neonatal intensive care unit after 16 years of routine fluconazole prophylaxis: no emergence of native fluconazole-resistant strains. *Am J Perinatol* 2019;36(S02):S126–S133. DOI: 10.1055/s-0039-1691808.
11. Che D, Zhou H, Li T, et al. Duration and intensity of fluconazole for prophylaxis in preterm neonates: a Meta-analysis of randomized controlled trials. *BMC Infect Dis* 2016;16(1):312. DOI: 10.1186/s12879-016-1645-5.
12. Bafeltowska JJ, Buszman E. Pharmacokinetics of fluconazole in the cerebrospinal fluid of children with hydrocephalus. *Chemotherapy* 2005;51(6):370–376. DOI: 10.1159/000088965.
13. Manosuthi W, Chetchotisakd P, Nolen TL, et al. BAMSG 3-01 study team. monitoring and impact of fluconazole Serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. *HIV Med* 2010;11(4):276–281. DOI: 10.1111/j.1468-1293.2009.00778.x.
14. Fisher JF, Sobel JD, Kauffman CA, et al. *Candida* urinary tract infections — treatment. *Clin Infect Dis* 2011;52(Suppl_6):S457–S466. DOI: 10.1093/cid/cir112.
15. Vazquez L. Antifungal prophylaxis in immunocompromised patients. *Mediterr J Hematol Infect Dis* 2016;8(1):e2016040. DOI: 10.4084/MJHID.2016.040.
16. Ullmann AJ, Aguado JM, Arian-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect* 2018;24(Suppl 1):e1–e38. DOI: 10.1016/j.cmi.2018.01.002.
17. Tsai M, Hsu J, Yang L, et al. Candidemia due to uncommon candida species in children: new threat and impacts on outcomes. *Sci Rep* 2018;8(1):15239. DOI: 10.1038/s41598-018-33662-x.
18. Garcia-Rubio R, Cuenca-Estrella M, Mellado E. Triazole resistance in Aspergillus species: an emerging problem. *Drugs* 2017;77(6):599–613. DOI: 10.1007/s40265-017-0714-4.
19. Sharpe AR, Lagrou K, Meis JF, et al. On behalf of the ISHAM/ECMM Aspergillus resistance surveillance working group. triazole resistance surveillance in *Aspergillus fumigatus*. *Med Mycol* 2018;56(suppl_1):S83–S92. DOI: 10.1093/mmy/myx144.
20. Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. *Eur J Clin Microbiol Infect Dis* 2014;33(4):629–631. DOI: 10.1007/s10096-013-1998-2.
21. Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by mucorales, *lomentspora prolificans* and *fusarium*, in San Diego, CA: the role of antifungal combination therapy. *Int J Antimicrob Agents* 2018;52(5):706–712. DOI: 10.1016/j.ijantimicag.2018.08.005.
22. Almannai M, Imran H, Estrada B, et al. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy. *Pediatr Hematol Oncol* 2013;30(3):184–186. DOI: 10.3109/08880018.2013.770587.
23. Page 2nd RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. *Pharmacotherapy* 2007;27(2):290–298. DOI: 10.1592/phco.27.2.290.
24. Taj-Aldeen SJ, Rammaert B, Gamaletsou M, et al. O, international osteoarticular mycoses consortium. osteoarticular infections caused by non-aspergillus filamentous fungi in adult and pediatric patients: a systematic review. *Medicine (Baltimore)* 2015;94(50):e2078. DOI: 10.1097/MD.000000000000207.
25. Sienkiewicz BM, Łapiński L, Wiela-Hojeńska A. Comparison of clinical pharmacology of voriconazole and posaconazole. *Contemp Oncol (Pozn)* 2016;20(5):365–373. DOI: 10.5114/wo.2016.64594.
26. Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. *Expert Rev Clin Pharmacol* 2015;8(3):321–334. DOI: 10.1586/17512433.2015.1034689.
27. Perlin DS. Echinocandin resistance in *Candida*. *Clin Infect Dis* 2015;61(Suppl 6):S612–S617. DOI: 10.1093/cid/civ791.
28. Pfeiffer CD, Gracia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. *J Clin Microbiol* 2010;48(7):2373–2380. DOI: 10.1128/JCM.02390-09.
29. Papp C, Kocsis K, Tóth R, et al. Echinocandin-induced microevolution of *Candida parapsilosis* influences virulence and abiotic stress tolerance. *mSphere* 2014;3(6):e00547-18.
30. Caudle KE, Inger AG, Butler DR, et al. Echinocandin use in the neonatal intensive care unit. *Ann Pharmacother* 2012;46(1):108–116. DOI: 10.1345/aph.1Q346.
31. Hope WW, Smith BP, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. *Antimicrob Agents Chemother* 2010;54(6):2633–2637. DOI: 10.1128/AAC.01679-09.
32. Pammi M, Holland L, Butler G, et al. *Candida parapsilosis* is a significant neonatal pathogen: a systematic review and meta-analysis. *Pediatr Infect Dis J* 2013;32(5):e206–e216. DOI: 10.1097/INF.0b013e3182863a1c.
33. Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous *Candida meningoenzephalitis*: identification of candidate regimens for humans using a translational pharmacological approach. *Antimicrob Agents Chemother* 2012;56(2):708–714. DOI: 10.1128/AAC.05826-11.
34. VandenBussche HL, Loo DAV. A clinical review of echinocandins in pediatric patients. *Ann Pharmacother* 2010;44(1):166–177. DOI: 10.1345/aph.1M139.
35. Ullmann S, Meert AJ, Paesmans L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European organisation for research and treatment of cancer study. *Bone Marrow Transplant* 2010;45(7):1227–1233. DOI: 10.1038/bmt.2009.334.
36. Mikulska M, Viscoli C. Current role of echinocandins in the management of invasive aspergillosis. *Curr Infect Dis Rep* 2011;13(6):517–527. DOI: 10.1007/s11908-011-0216-6.